Skip to main content

Table 1 Patient demographics (n = 26)

From: Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial

Age, years (±SD) 61 ± 9
Male sex, no (%) 19 (73)
Smokers, no (%) 13 (50)
Body mass index, kg/m2 (±SD) 26.7 ± 4.6
Office blood pressure, mmHg (±SD) 136/83 ± 13/9
Medication, no (%)
Calcium channel blockers 20 (77)
Alpha blockers 1 (4)
Beta blockers 16 (62)
Minoxidil 7 (27)
Loop diuretics 16 (62)
Thiazide diuretics 3 (12)
Spironolactone 2 (8)
Allopurinol 3 (12)
Statins 16 (62)
Number of antihypertensive agents (±SD) 2.5 (1.3)
Routine Biochemistry (±SD)
eGFR, ml/min/1.73 m2 (MDRD) 26 ± 11
p-Creatinine, μmol/l 231 ± 78
p-Ca++ 1.22 ± 0.05
p-Phosphate, mmol/l 1.19 ± 0.27
p-Cholesterol (total), mmol/l 5.0 ± 1.2
p-Hemoglobin, mmol/l 8.3 ± 0.8
p-Albumin, g/l 43 ± 3
u-Albumin, mg/l 169 [Interquartile range: 59;489]
P25(OH)D2+3, nmol/l 56 ± 21
Primary kidney disease, no (%)  
Glomerulonephritis 6 (23)
Polycystic kidney disease 3 (12)
Chronic interstitial nephritis 2 (8)
Unknown* 15 (58)
  1. *Renal biopsy deferred due to advanced stage of kidney disease on admission, reduced kidney size on radiologic examination and absence of nephrotic syndrome.